Search by Drug Name or NDC
NDC 68974-0400-30 FILSPARI 400 mg/1 Details
FILSPARI 400 mg/1
FILSPARI is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Travere Therapeutics, Inc.. The primary component is SPARSENTAN.
MedlinePlus Drug Summary
Sparsentan is used reduce proteinuria (increased protein in urine) in certain patients with primary immunoglobulin A (IgA) nephropathy (a kidney disease where IgA deposits build up in the kidneys causing inflammation). Sparsentan is in a class of medications called endothelin and angiotensin II receptor antagonists. It works by blocking two substances, endothelin and angiotensin II, that play a role in the progression of kidney disease.
Related Packages: 68974-0400-30Last Updated: 05/05/2024
MedLinePlus Full Drug Details: Sparsentan
Product Information
NDC | 68974-0400 |
---|---|
Product ID | 68974-400_6ed15d2c-3348-4c27-9853-414cb9e4bb94 |
Associated GPIs | |
GCN Sequence Number | 084438 |
GCN Sequence Number Description | sparsentan TABLET 400 MG ORAL |
HIC3 | A4Q |
HIC3 Description | ENDOTHELIN-ANGIOTENSIN RECEPTOR ANTAGONIST |
GCN | 53743 |
HICL Sequence Number | 048721 |
HICL Sequence Number Description | SPARSENTAN |
Brand/Generic | Brand |
Proprietary Name | FILSPARI |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | sparsentan |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET, FILM COATED |
Route | ORAL |
Active Ingredient Strength | 400 |
Active Ingredient Units | mg/1 |
Substance Name | SPARSENTAN |
Labeler Name | Travere Therapeutics, Inc. |
Pharmaceutical Class | n/a |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA216403 |
Listing Certified Through | 2024-12-31 |
Package
NDC 68974-0400-30 (68974040030)
NDC Package Code | 68974-400-30 |
---|---|
Billing NDC | 68974040030 |
Package | 30 TABLET, FILM COATED in 1 BOTTLE (68974-400-30) |
Marketing Start Date | 2023-02-17 |
NDC Exclude Flag | N |
Pricing Information | N/A |